您当前位置：首页 > 国际期刊-PSYCHOPHARMACOLOGY期刊投稿发表详细信息

PSYCHOPHARMACOLOGY Q2

期刊收录：
SCIE
Scopus

基本信息

期刊ISSN：
0033-3158
期刊简拼：
PSYCHOPHARMACOLOGY
年发文章数：
201
E-ISSN：
1432-2072
Gold OA文章占比
29.69%
研究文章占比：
91.04%
是否OA：
No
Jcr分区：
Q2
中科院分区：
3区

出版信息

出版商：
Springer Berlin Heidelberg
涉及研究方向：
医学-精神病学
出版国家：
GERMANY
出版语言：
English
出版周期：
Semimonthly
出版年份：
1959

2023-2024最新影响因子:3.5
自引率:2.90%
五年影响因子:3.6
JCI期刊引文指标:0.92
h-index:181
CiteScore:7.10

期刊关键词

2区 SCIE Scopus 医学 3区 NEUROSCIENCES 神经科学 PHARMACOLOGY & PHARMACY 药学 PSYCHIATRY 精神病学

期刊简介

Official Journal of the European Behavioural Pharmacology Society (EBPS)

Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

Human Psychopharmacology: Experimental

This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

Human Psychopharmacology: Clinical and Translational

This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

Preclinical psychopharmacology: Behavioral and Neural

This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

Preclinical Psychopharmacology: Translational

This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.